INT299751

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2005
Last Reported 2005
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.78
Pain Relevance 1.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
Etanercept 44 98.44 Very High Very High Very High
methotrexate 148 97.52 Very High Very High Very High
rheumatoid arthritis 94 87.60 High High
abatacept 16 9.12 Low Low
Infliximab 34 5.00 Very Low Very Low Very Low
Adalimumab 34 5.00 Very Low Very Low Very Low
anakinra 12 5.00 Very Low Very Low Very Low
Inflammation 10 5.00 Very Low Very Low Very Low
Leflunomide 6 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 36 99.84 Very High Very High Very High
Rheumatoid Arthritis 96 87.60 High High
Infection 8 68.28 Quite High
INFLAMMATION 12 5.00 Very Low Very Low Very Low
Necrosis 10 5.00 Very Low Very Low Very Low
Cancer 10 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Demyelinating Disease 2 5.00 Very Low Very Low Very Low
Toxicity 2 5.00 Very Low Very Low Very Low
Heart Rate Under Development 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compared with patients who received methotrexate, patients taking the 25 mg dose of etanercept exhibited a more rapid rate of improvement, with significantly more patients having ACR20, ACR50, and ACR70 response improvement in disease activity during the first 6 months (P < 0.05).
Positive_regulation (having) of Positive_regulation (improvement) of ACR20 associated with disease, etanercept and methotrexate
1) Confidence 0.05 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833970 Disease Relevance 0.39 Pain Relevance 0.80
Compared with patients who received methotrexate, patients taking the 25 mg dose of etanercept exhibited a more rapid rate of improvement, with significantly more patients having ACR20, ACR50, and ACR70 response improvement in disease activity during the first 6 months (P < 0.05).
Positive_regulation (having) of Positive_regulation (improvement) of ACR70 associated with disease, etanercept and methotrexate
2) Confidence 0.05 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833970 Disease Relevance 0.39 Pain Relevance 0.80

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox